Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 1.00 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.68 |
| ▸ | VCP | P55072 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.60 |
| ▸ | TUBB | P07437 | 2/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.60 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.60 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.60 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.60 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.60 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.60 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.60 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.60 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4785927 | 1.00 | PTGS2 (1.00) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL1032986 | 0.88 | PTGS2 (0.78) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL13018896 | 0.88 | PTGS2 (0.78) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL1032987 | 0.88 | PTGS2 (0.78) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL4260150 | 0.87 | PTGS2 (0.77) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL4260145 | 0.87 | PTGS2 (0.77) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL4257103 | 0.86 | PTGS2 (0.75) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL4257101 | 0.86 | PTGS2 (0.75) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL4254962 | 0.86 | PTGS2 (0.76) | PTGS2CYP19A1TLR9VCPPTGS1 | |
| SCHEMBL4254966 | 0.86 | PTGS2 (0.76) | PTGS2CYP19A1TLR9VCPPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0221346-B1 | (N-SUBSTITUTED-2-HYDROXY) BENZAMIDES AND N-SUBSTITUTED-2-HYDROXY-ALPHA-OXO-BENZENEACETAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF HAVING ACTIVITY AS MODULATORS OF THE ARACHIDONIC ACID CASCADE | WARNER-LAMBERT COMPANY (US) | 1991-01-30 | — | — | EP | disclosed |
| US-4939133-A | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
| US-4921871-A | LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| US-4874758-A | LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| US-4868205-A | ANTIALLERGENS, ANTIINFLAMMATORY, CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868200-A | LEUKOTRIENES, LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868195-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868199-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4761424-A | Enolamides, pharmaceutical compositions and methods for treating inflammation | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0221346-A1 | (N-substituted-2-hydroxy) benzamides and N-substituted-2-hydroxy-alpha-oxo-benzeneacetamides and pharmaceutical compositions thereof having activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
| EP-0221345-A1 | Novel enolamides, process for their manufacture and pharmaceutical compositions thereof with an activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | APP, PSEN1, BACE1 | PTGS2 3460/4885CYP19A1 3180/4885TLR9 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.